LTR Pharma has officially debuted on the Australian Securities Exchange (ASX) under ticker code LTP.
Our foremost priority is to execute a bioequivalence trial of SPONTAN® to support expedited regulatory approvals, and to market and sell SPONTAN in the United States and Australia, first.
We have a highly experienced team of pharmaceutical developers and commercialisation experts driving this program forward – and valued investors backing us too.
Successful phase I human proof of concept study now complete. SPONTAN® has shown to be six times faster than oral PDE5 inhibitors.
On track to register the first PDE5 inhibitor nasal spray, in a market estimated to reach US$6.0B in 2028.
Progressing to bioequivalence study, with expedited regulatory filings in the United States and Australia within 1-2 years.
View our Shareholder Communications summary here
View our Corporate Directory here
In recognition of September being Sexual Health Awareness Month, we’re pleased to share the latest episode of our Conversation Series, featuring Sexologist and Nurse Practitioner
Clinical collaborator and men’s health expert Melissa Hadley Barrett from Make Hard Easy and the Restorative Health Clinic presented a case series at the Asia-Pacific
LTR Pharma has announced that SPONTAN® has achieved an 18-month shelf life under International Council for Harmonisation (ICH) stability conditions – a significant milestone that